170 related articles for article (PubMed ID: 19116635)
1. Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication.
Aghi MK; Chiocca EA
Mol Ther; 2009 Jan; 17(1):8-9. PubMed ID: 19116635
[No Abstract] [Full Text] [Related]
2. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.
Markert JM; Liechty PG; Wang W; Gaston S; Braz E; Karrasch M; Nabors LB; Markiewicz M; Lakeman AD; Palmer CA; Parker JN; Whitley RJ; Gillespie GY
Mol Ther; 2009 Jan; 17(1):199-207. PubMed ID: 18957964
[TBL] [Abstract][Full Text] [Related]
3. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study.
Miller KE; Cassady KA; Roth JC; Clements J; Schieffer KM; Leraas K; Miller AR; Prasad N; Leavenworth JW; Aban IB; Whitley RJ; Gillespie GY; Mardis ER; Markert JM
Clin Cancer Res; 2022 Feb; 28(3):498-506. PubMed ID: 35105718
[TBL] [Abstract][Full Text] [Related]
4. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas.
Mineta T; Rabkin SD; Yazaki T; Hunter WD; Martuza RL
Nat Med; 1995 Sep; 1(9):938-43. PubMed ID: 7585221
[TBL] [Abstract][Full Text] [Related]
5. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.
Markert JM; Medlock MD; Rabkin SD; Gillespie GY; Todo T; Hunter WD; Palmer CA; Feigenbaum F; Tornatore C; Tufaro F; Martuza RL
Gene Ther; 2000 May; 7(10):867-74. PubMed ID: 10845725
[TBL] [Abstract][Full Text] [Related]
6. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia enhances the replication of oncolytic herpes simplex virus.
Aghi MK; Liu TC; Rabkin S; Martuza RL
Mol Ther; 2009 Jan; 17(1):51-6. PubMed ID: 18957963
[TBL] [Abstract][Full Text] [Related]
8. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus.
Todo T; Rabkin SD; Sundaresan P; Wu A; Meehan KR; Herscowitz HB; Martuza RL
Hum Gene Ther; 1999 Nov; 10(17):2741-55. PubMed ID: 10584921
[TBL] [Abstract][Full Text] [Related]
9. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of brain tumors using neural stem cells and replication-conditional virus].
Yazaki T; Kanai R; Kawase T
Nihon Rinsho; 2005 Sep; 63 Suppl 9():551-6. PubMed ID: 16201580
[No Abstract] [Full Text] [Related]
11. Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer.
Lin SF; Gao SP; Price DL; Li S; Chou TC; Singh P; Huang YY; Fong Y; Wong RJ
Clin Cancer Res; 2008 Mar; 14(5):1519-28. PubMed ID: 18316577
[TBL] [Abstract][Full Text] [Related]
12. Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model.
Alessandrini F; Menotti L; Avitabile E; Appolloni I; Ceresa D; Marubbi D; Campadelli-Fiume G; Malatesta P
Oncogene; 2019 Jun; 38(23):4467-4479. PubMed ID: 30755732
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy.
Todo T; Rabkin SD; Chahlavi A; Martuza RL
Hum Gene Ther; 1999 Nov; 10(17):2869-78. PubMed ID: 10584932
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
15. Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.
Bernstock JD; Bag AK; Fiveash J; Kachurak K; Elsayed G; Chagoya G; Gessler F; Valdes PA; Madan-Swain A; Whitley R; Markert JM; Gillespie GY; Johnston JM; Friedman GK
Hum Gene Ther; 2020 Oct; 31(19-20):1132-1139. PubMed ID: 32657154
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic replication-competent herpes virus.
Rampling R; Cruickshank G; MacLean A; Brown M
Nat Med; 1998 Feb; 4(2):133. PubMed ID: 9461166
[No Abstract] [Full Text] [Related]
17. Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis.
Cinatl J; Michaelis M; Driever PH; Cinatl J; Hrabeta J; Suhan T; Doerr HW; Vogel JU
Neoplasia; 2004; 6(6):725-35. PubMed ID: 15720798
[TBL] [Abstract][Full Text] [Related]
18. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model.
Cozzi PJ; Malhotra S; McAuliffe P; Kooby DA; Federoff HJ; Huryk B; Johnson P; Scardino PT; Heston WD; Fong Y
FASEB J; 2001 May; 15(7):1306-8. PubMed ID: 11344122
[No Abstract] [Full Text] [Related]
19. [Gene therapy for brain tumors using herpes simplex virus vector].
Toda M
Nihon Rinsho; 2005 Sep; 63 Suppl 9():510-4. PubMed ID: 16201573
[No Abstract] [Full Text] [Related]
20. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial.
Prados MD; McDermott M; Chang SM; Wilson CB; Fick J; Culver KW; Van Gilder J; Keles GE; Spence A; Berger M
J Neurooncol; 2003 Dec; 65(3):269-78. PubMed ID: 14682377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
